195 related articles for article (PubMed ID: 34638879)
1. Blockade of Glycosphingolipid Synthesis Inhibits Cell Cycle and Spheroid Growth of Colon Cancer Cells In Vitro and Experimental Colon Cancer Incidence In Vivo.
Jennemann R; Volz M; Bestvater F; Schmidt C; Richter K; Kaden S; Müthing J; Gröne HJ; Sandhoff R
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638879
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.
Salustiano EJ; da Costa KM; Freire-de-Lima L; Mendonça-Previato L; Previato JO
J Biol Chem; 2020 May; 295(19):6457-6471. PubMed ID: 32229586
[TBL] [Abstract][Full Text] [Related]
3. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.
Chai L; McLaren RP; Byrne A; Chuang WL; Huang Y; Dufault MR; Pacheco J; Madhiwalla S; Zhang X; Zhang M; Teicher BA; Carter K; Cheng SH; Leonard JP; Xiang Y; Vasconcelles M; Goldberg MA; Copeland DP; Klinger KW; Lillie J; Madden SL; Jiang YA
Int J Oncol; 2011 Mar; 38(3):701-11. PubMed ID: 21186402
[TBL] [Abstract][Full Text] [Related]
4. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models.
Natoli TA; Smith LA; Rogers KA; Wang B; Komarnitsky S; Budman Y; Belenky A; Bukanov NO; Dackowski WR; Husson H; Russo RJ; Shayman JA; Ledbetter SR; Leonard JP; Ibraghimov-Beskrovnaya O
Nat Med; 2010 Jul; 16(7):788-92. PubMed ID: 20562878
[TBL] [Abstract][Full Text] [Related]
6. Reducing glycosphingolipid biosynthesis in airway cells partially ameliorates disease manifestations in a mouse model of asthma.
Karman J; Tedstone JL; Gumlaw NK; Zhu Y; Yew N; Siegel C; Guo S; Siwkowski A; Ruzek M; Jiang C; Cheng SH
Int Immunol; 2010 Jul; 22(7):593-603. PubMed ID: 20497953
[TBL] [Abstract][Full Text] [Related]
7. Hepatic glycosphingolipid deficiency and liver function in mice.
Jennemann R; Rothermel U; Wang S; Sandhoff R; Kaden S; Out R; van Berkel TJ; Aerts JM; Ghauharali K; Sticht C; Gröne HJ
Hepatology; 2010 May; 51(5):1799-809. PubMed ID: 20432257
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy.
Pavlova EV; Archer J; Wang S; Dekker N; Aerts JM; Karlsson S; Cox TM
J Pathol; 2015 Jan; 235(1):113-24. PubMed ID: 25256118
[TBL] [Abstract][Full Text] [Related]
9. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?
Shayman JA
Trans Am Clin Climatol Assoc; 2013; 124():46-60. PubMed ID: 23874009
[TBL] [Abstract][Full Text] [Related]
10. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.
Nietupski JB; Pacheco JJ; Chuang WL; Maratea K; Li L; Foley J; Ashe KM; Cooper CG; Aerts JM; Copeland DP; Scheule RK; Cheng SH; Marshall J
Mol Genet Metab; 2012 Apr; 105(4):621-8. PubMed ID: 22366055
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons.
Shen W; Henry AG; Paumier KL; Li L; Mou K; Dunlop J; Berger Z; Hirst WD
J Neurochem; 2014 Jun; 129(5):884-94. PubMed ID: 24494600
[TBL] [Abstract][Full Text] [Related]
12. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
[TBL] [Abstract][Full Text] [Related]
13. Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase.
Gupta V; Patwardhan GA; Zhang QJ; Cabot MC; Jazwinski SM; Liu YY
J Lipid Res; 2010 Apr; 51(4):866-74. PubMed ID: 19826105
[TBL] [Abstract][Full Text] [Related]
14. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.
Ersek A; Xu K; Antonopoulos A; Butters TD; Santo AE; Vattakuzhi Y; Williams LM; Goudevenou K; Danks L; Freidin A; Spanoudakis E; Parry S; Papaioannou M; Hatjiharissi E; Chaidos A; Alonzi DS; Twigg G; Hu M; Dwek RA; Haslam SM; Roberts I; Dell A; Rahemtulla A; Horwood NJ; Karadimitris A
J Clin Invest; 2015 Jun; 125(6):2279-92. PubMed ID: 25915583
[TBL] [Abstract][Full Text] [Related]
15. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
Ashe KM; Bangari D; Li L; Cabrera-Salazar MA; Bercury SD; Nietupski JB; Cooper CG; Aerts JM; Lee ER; Copeland DP; Cheng SH; Scheule RK; Marshall J
PLoS One; 2011; 6(6):e21758. PubMed ID: 21738789
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis.
Jennemann R; Federico G; Mathow D; Rabionet M; Rampoldi F; Popovic ZV; Volz M; Hielscher T; Sandhoff R; Gröne HJ
Oncotarget; 2017 Dec; 8(65):109201-109216. PubMed ID: 29312601
[TBL] [Abstract][Full Text] [Related]
17. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.
Liu YY; Hill RA; Li YT
Adv Cancer Res; 2013; 117():59-89. PubMed ID: 23290777
[TBL] [Abstract][Full Text] [Related]
18. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice.
Zhao H; Przybylska M; Wu IH; Zhang J; Maniatis P; Pacheco J; Piepenhagen P; Copeland D; Arbeeny C; Shayman JA; Aerts JM; Jiang C; Cheng SH; Yew NS
Hepatology; 2009 Jul; 50(1):85-93. PubMed ID: 19444873
[TBL] [Abstract][Full Text] [Related]
20. Cell-specific in vivo functions of glycosphingolipids: lessons from genetic deletions of enzymes involved in glycosphingolipid synthesis.
Jennemann R; Gröne HJ
Prog Lipid Res; 2013 Apr; 52(2):231-48. PubMed ID: 23473748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
